Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: An EORTC- HOVON randomized phase III study (06914)

British Journal of Haematology

Volumn 115, Issue 4, 2001, Pages 895-902

  Sonneveld, P ^a   Suciu, S ^a   Weijermans, P ^a   Beksac, M ^a   Neuwirtova, R ^a   Solbu, G ^a   Lokhorst, H ^a   Van der Lelie, J ^a   Dohner, H ^a   Gerhartz, H ^a   Segeren, C M ^a   Willemze, R ^a   Lowenberg, B ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cyclosporin A; Multidrug resistance (MDR); Multiple myeloma; Reversal of multidrug resistance (MDR)

Indexed keywords

ALKYLATING AGENT; CYCLOSPORIN A; DEXAMETHASONE; DOXORUBICIN; GLYCOPROTEIN P; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TOLERANCE; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHI-SQUARE DISTRIBUTION; CYCLOSPORINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; P-GLYCOPROTEIN; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL RATE; VINCRISTINE;

EID: 0035673972     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.03171.x     Document Type: Article

References (28)

1. Combination chemotherapy for multiple myeloma
2. Clinical significance of P-glycoprotein in multidrug resistance malignancies
3. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
4. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma. Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy
5. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma
6. In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells
7. Reversal of drug resistance in multiple myeloma with verapamil
8. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD
9. Expression of a multi-drug resistance gene in human tumors and tissues
10. Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance
11. Cellular resistance mechanisms with impact on the therapy of multiple myeloma
12. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials
13. Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies
14. P-glycopro-tein expression in human plasma cell myeloma: Correlation with prior chemotherapy
15. Expression of mdr1 and mdr2 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine
16. Drug resistance in multiple myeloma: Cyclosporin A analogues and their metabolites as potential chemosensitizers
17. Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma
18. Multidrug-resistant myeloma: Laboratory and clinical effects of verapamil as a chemosensitizer
19. Infusions of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma
20. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid fusion for first-line treatment in untreated multiple myeloma
21. P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma
22. Drug resistance in multiple myeloma
23. Modulation of multidrug resistance by cyclosporin
24. Clinical modulation of multidrug resistance in multiple myeloma
25. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study
26. Potentiation of vincristine and adriamycin effects in human hematopoietic tumor cells lines by calcium cannel antagonists and calmodulin inhibitors